Aggressive B-Zell-Lymphome

GOAL II

Status: aktiv, Eudract Nr. 2019-002373-59
A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma
Ansprechpartner:
Prof. Dr. Gerald Illerhaus
Telefon: 0711 278-30401
E-Mail: g.illerhaus@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de